Aim To compare the localization of lung adenocarcinoma with tumour size and lymphovascular invasion (LVI) presence, and to determine the frequency of metastasis findings in hilar and mediastinal lymph nodes depending on the localization of the tumour and status of lymphovascular invasion. Method This observational cross-sectional study included 261 patients with complete resection of confirmed lung adenocarcinoma. The dependence between categorical variables were performed with χ2 and Fisher's exact tests. A p<0.05 was considered as statistically significant. Result Metastases to hilar lymph nodes at lung adenocarcinoma with central localization and presented lymphovascular invasion were more frequently found than tumours with peripheral localization (p<0.001). In tumours with peripheral localization, lymphovascular invasion was less frequent; even in tumours greater than 7 cm in the largest dimension the presence of LVI was not 100%. Metastases to mediastinal lymph nodes in tumours with central localization and presented lymphovascular invasion were less frequent than in tumours with peripheral localization and presented lymphovascular invasion (p=0.002). Conclusion In invasive adenocarcinoma, lymphovascular invasion was much more common in centrally positioned than in peripherally positioned tumours. Metastases to the hilar and mediastinal lymph nodes, regardless of the findings of lymphovascular invasion, usually originated from upper lobe tumours.
Yang L, Wang S, Gerber D, Zhou Y, Xu F, Liu J, et al. Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma; A large cohort analysis. Lung Cancer. 2018;22–6.
2.
Seok Y, Yang H, Kim T, Lee K, Kim K, Jheon S, et al. Frequency of lymph hode metastasis according to the size of tumors in resected pulmonary adenocarcinoma with a size of 30mm or smaller. J Thorac Oncol. 2014;818–24.
3.
Cerfolio R, Bryant A. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg. 2006;1969–73.
4.
Ketchedjian A, Daly B, Fernando H, Florin L, Hunter C, Morelli D, et al. Location as an important predictor of lymph node involvement for pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2006;544–8.
5.
Cho S, Kim K, Jheon S. Characteristics and prognostic factors of node-negative non-small cell lung cancer larger than 5 cm. Interact Cardiovasc Thorac Surg. 2017;448–54.
6.
Funai K, Sugimura H, Morita T, Shundo Y, Shimizu K, Shiiya N. Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol. 2011;2968–72.
7.
Mollberg N, Bennette C, Howell E, Backhus L, Devine B, Ferguson M. Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and metaanalysis. Ann Thorac Surg. 2014;965–71.
8.
Sakao Y, Okumura S, Mingyon M, Uehara H, Ishikawa Y, Nakagawa K. The impact of superior mediastinal lymph node metastases on prognosis in nonsmall cell lung cancer located in the right middle lobe. J Thorac Oncol. 2011;494–9.
9.
Chao-Yu L, Jung-Jyh, H, Yen B, W, Hu W, et al. Prognostic factors in resected pathological N1-stage II non-small cell lung cancer. Eur Resp J. 2013;649–55.
10.
Chanyeong P, In J, Seung H, Jae. Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence. J Thorac Dis. 2014;1420–8.
11.
Kotoulas C, Foroulis C, Kostikas K, Kostantinou M, Kalkandi P, Dirmadi M, et al. Involvement of lymphatic metastatic spread in nonsmall cell lung cancer accordingly to the primary cancer location. Lung Cancer. 2004;183–91.
12.
Higgins K, Chino J, Ready N, ’amico D, Berry T, Sporn M, et al. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol. 2012;1141–7.
13.
Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;990–1003.
14.
Samson P, Crabtreet, Broderick S, Kreisel D, Krupnick A, Patterson G, et al. Quality measures in clinical stage I non-small cell lung cancer: Improved performance is associated with improved survival. Ann Thorac Surg. 2017;303–11.
15.
Youngkyu M, Kyo Y, Sook W. Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. J Thorac Dis. 2016;169–77.
16.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLO-BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer. J Clin. 2018;394–424.
17.
Sun W, Yang X, Liu Y, Yuan Y, Lin D. Primary tumor location is a useful predictor for lymph node metastasis and prognosis in lung adenocarcinoma. Clinical Lung Cancer. 2017;49–55.
18.
Lee J, Lee C, Park I, Kim D, Park S, Kim K, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg. 2008;211–5.
19.
Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, et al. Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer. 2012;394–400.
20.
Okiror L, Harling L, Toufektzian L, King J, Routledge T, Harrison-Phipps K. Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018;785–93.
21.
Noma D, Inamura K, Matsuuray, Hiratay NK, Yamazaki H, Hirai Y, et al. Prognostic effect of lymphovascular invasion on TNM staging in stage I non-small-cell lung cancer. Clin Lung Cancer. 2018;109–22.
22.
Sung S, Kwak Y, Lee S, Jo I, Park J, Kim K, et al. Lymphovascular invasion increases the risk of nodal and distant recurrence in node-negative stage I-IIA non-small-cell lung cancer. Oncology. 2018;156–62.
23.
Petersen I. Adenocarcinome der Lunge -die neue Klassification. Zentralbl Chir. 2013;16–24.
24.
Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beaslex M, et al. The 2015 World Healt Organizati-onClassification of Lung Tumors:impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;1243–60.
25.
Rassaei N. Adenocarcnoma-classification. 20AD;
26.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;359–86.
27.
Cancer Facts & Figures. 2014;
28.
Zappa C, Mousa S. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;288–300.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
